Figure 3
From: Kinome expression profiling and prognosis of basal breast cancers
Disease-free survival and basal subgroups in the validation set. Kaplan-Meier disease-free survival curves of basal BC patients in the independent validation series according to the subgroups "Immune-High" and "Immune-Low". (A) in all patients (95 versus 285 patients respectively), and (B) in patients having received no systemic adjuvant therapy (39 versus 148 patients respectively).